Announcements 02 August 2021

– HMBD-001 is the first clinical stage asset generated by Hummingbird’s proprietary Rational Antibody Discovery (RAD) platform Houston and Singapore,...

Announcements 26 July 2021

Houston and Singapore, July 26, 2021 – Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against...

Announcements 12 July 2021

– Multi-year collaboration will investigate and evaluate Hummingbird’s HMBD-002 VISTA antagonist antibody Houston and Singapore, July 12, 2021 – Hummingbird...

Announcements 15 June 2021

Houston, TX, and Singapore, June 14, 2021 – Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies...

Announcements 09 June 2021

-- Partnership will enhance biomarker-driven patient enrollment in clinical trials of Hummingbird Bioscience’s lead program, HMBD-001 Houston, TX, and Singapore,...

Announcements 31 May 2021

- HMBD-002 is the only IgG4 isotype anti-VISTA antibody currently in development- HMBD-002 is anticipated to enter a Phase 1...

Announcements 27 May 2021

Pharma Intelligence’s Insights speaks to Hummingbird CEO Piers Ingram following the Singapore-based company’s Series C financing round.

Announcements 27 May 2021

Hummingbird discusses our HER3 program and how we are tackling the challenges of therapeutics development.